143 related articles for article (PubMed ID: 3504088)
21. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate.
Thestrup-Pedersen K; Hammer R; Kaltoft K; Søgaard H; Zachariae H
Br J Dermatol; 1988 Jun; 118(6):811-8. PubMed ID: 3042011
[TBL] [Abstract][Full Text] [Related]
22. Recombinant interferon alfa-2a, an active agent in advanced cutaneous T-cell lymphomas.
Bunn PA; Ihde DC; Foon KA
Int J Cancer Suppl; 1987; 1():9-13. PubMed ID: 3305390
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Foss F; Gupta R; Kuzel TM
J Am Acad Dermatol; 2007 Apr; 56(4):580-3. PubMed ID: 17367611
[TBL] [Abstract][Full Text] [Related]
24. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
25. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma.
Olsen EA; Rosen ST; Vollmer RT; Variakojis D; Roenigk HH; Diab N; Zeffren J
J Am Acad Dermatol; 1989 Mar; 20(3):395-407. PubMed ID: 2783939
[TBL] [Abstract][Full Text] [Related]
26. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.
Bunn PA; Foon KA; Ihde DC; Longo DL; Eddy J; Winkler CF; Veach SR; Zeffren J; Sherwin S; Oldham R
Ann Intern Med; 1984 Oct; 101(4):484-7. PubMed ID: 6332565
[TBL] [Abstract][Full Text] [Related]
27. Peginterferon alfa-2b for mycosis fungoides.
Yanagi T; Shimizu T; Ujiie H; Ito M; Abe R; Tsuji-Abe Y; Hige S; Shimizu H
Arch Dermatol; 2006 May; 142(5):649-51. PubMed ID: 16702510
[No Abstract] [Full Text] [Related]
28. Mycosis fungoides: progression towards Sézary syndrome reversed with chlorambucil.
Holmes RC; McGibbon DH; Black MM
Clin Exp Dermatol; 1983 Jul; 8(4):429-35. PubMed ID: 6627736
[No Abstract] [Full Text] [Related]
29. Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
Ho AD; Suciu S; Stryckmans P; De Cataldo F; Willemze R; Thaler J; Peetermans M; Döhner H; Solbu G; Dardenne M; Zittoun R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):52-7. PubMed ID: 10877053
[TBL] [Abstract][Full Text] [Related]
30. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
Altomare GF; Capella GL; Pigatto PD; Finzi AF
Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
[TBL] [Abstract][Full Text] [Related]
31. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of interferon alfa-2a, recombinant (Roferon-A) in metastatic renal cell carcinoma.
Buzaid AC; Robertone A; Kisala C; Salmon SE
J Clin Oncol; 1987 Jul; 5(7):1083-9. PubMed ID: 3598612
[TBL] [Abstract][Full Text] [Related]
34. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
[TBL] [Abstract][Full Text] [Related]
35. [Interferon-alpha and PUVA therapy for mycosis fungoides].
Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
[TBL] [Abstract][Full Text] [Related]
36. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
37. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
38. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.
Kuzel TM; Gilyon K; Springer E; Variakojis D; Kaul K; Bunn PA; Evans L; Roenigk HH; Rosen ST
J Natl Cancer Inst; 1990 Feb; 82(3):203-7. PubMed ID: 2296050
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune haemolytic anaemia associated with interferon alfa-2a in a patient with mycosis fungoides.
Braathen LR; Stavem P
BMJ; 1989 Jun; 298(6689):1713. PubMed ID: 2503190
[No Abstract] [Full Text] [Related]
40. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
